243 related articles for article (PubMed ID: 18291115)
1. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer.
Lafky JM; Wilken JA; Baron AT; Maihle NJ
Biochim Biophys Acta; 2008 Apr; 1785(2):232-65. PubMed ID: 18291115
[TBL] [Abstract][Full Text] [Related]
2. Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer.
Baron AT; Wilken JA; Haggstrom DE; Goodrich ST; Maihle NJ
IDrugs; 2009 May; 12(5):302-8. PubMed ID: 19431095
[TBL] [Abstract][Full Text] [Related]
3. Trophoblast subtype-specific EGFR/ERBB4 expression correlates with cell cycle progression and hyperplasia in complete hydatidiform moles.
Fock V; Plessl K; Fuchs R; Dekan S; Milla SK; Haider S; Fiala C; Knöfler M; Pollheimer J
Hum Reprod; 2015 Apr; 30(4):789-99. PubMed ID: 25740878
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
5. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
6. Biological response to ErbB ligands in nontransformed cell lines correlates with a specific pattern of receptor expression.
Sundaresan S; Roberts PE; King KL; Sliwkowski MX; Mather JP
Endocrinology; 1998 Dec; 139(12):4756-64. PubMed ID: 9832411
[TBL] [Abstract][Full Text] [Related]
7. ErbB Receptors and Cancer.
Wang Z
Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
[TBL] [Abstract][Full Text] [Related]
8. The neuregulin-I/ErbB signaling system in development and disease.
Britsch S
Adv Anat Embryol Cell Biol; 2007; 190():1-65. PubMed ID: 17432114
[TBL] [Abstract][Full Text] [Related]
9. EGF/ErbB receptor family in ovarian cancer.
Maihle NJ; Baron AT; Barrette BA; Boardman CH; Christensen TA; Cora EM; Faupel-Badger JM; Greenwood T; Juneja SC; Lafky JM; Lee H; Reiter JL; Podratz KC
Cancer Treat Res; 2002; 107():247-58. PubMed ID: 11775453
[TBL] [Abstract][Full Text] [Related]
10. Granulosa cell tumors express erbB4 and are sensitive to the cytotoxic action of heregulin-beta2/PE40.
Furger C; Fiddes RJ; Quinn DI; Bova RJ; Daly RJ; Sutherland RL
Cancer Res; 1998 May; 58(9):1773-8. PubMed ID: 9581810
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor (EGFR) signaling in cancer.
Normanno N; De Luca A; Bianco C; Strizzi L; Mancino M; Maiello MR; Carotenuto A; De Feo G; Caponigro F; Salomon DS
Gene; 2006 Jan; 366(1):2-16. PubMed ID: 16377102
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors.
Alimandi M; Wang LM; Bottaro D; Lee CC; Kuo A; Frankel M; Fedi P; Tang C; Lippman M; Pierce JH
EMBO J; 1997 Sep; 16(18):5608-17. PubMed ID: 9312020
[TBL] [Abstract][Full Text] [Related]
13. HER2 mediates epidermal growth factor-induced down-regulation of E-cadherin in human ovarian cancer cells.
Cheng JC; Qiu X; Chang HM; Leung PC
Biochem Biophys Res Commun; 2013 Apr; 434(1):81-6. PubMed ID: 23542467
[TBL] [Abstract][Full Text] [Related]
14. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder.
Chow NH; Chan SH; Tzai TS; Ho CL; Liu HS
Clin Cancer Res; 2001 Jul; 7(7):1957-62. PubMed ID: 11448910
[TBL] [Abstract][Full Text] [Related]
15. ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium.
Fuller SJ; Sivarajah K; Sugden PH
J Mol Cell Cardiol; 2008 May; 44(5):831-54. PubMed ID: 18430438
[TBL] [Abstract][Full Text] [Related]
16. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B
Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604
[TBL] [Abstract][Full Text] [Related]
17. Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy.
Tsujioka H; Yotsumoto F; Hikita S; Ueda T; Kuroki M; Miyamoto S
Curr Opin Obstet Gynecol; 2011 Feb; 23(1):24-30. PubMed ID: 20966750
[TBL] [Abstract][Full Text] [Related]
18. The ErbB/HER receptor protein-tyrosine kinases and cancer.
Roskoski R
Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of EGFR family-mediated HRG signals in human ovarian cancer.
Campiglio M; Ali S; Knyazev PG; Ullrich A
J Cell Biochem; 1999 Jun; 73(4):522-32. PubMed ID: 10733345
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer.
Tanaka Y; Miyamoto S; Suzuki SO; Oki E; Yagi H; Sonoda K; Yamazaki A; Mizushima H; Maehara Y; Mekada E; Nakano H
Clin Cancer Res; 2005 Jul; 11(13):4783-92. PubMed ID: 16000575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
